Remed Co

Remed Co FCF Growth

The Year-over-Year Free Cash Flow Growth of Remed Co (302550.KQ) as of Nov 19, 2026 is 140.28 %. In the previous year, Year-over-Year Free Cash Flow Growth was -75.60 % — a change of -285.56% (higher).

FCF Growth

140.28 %

YoY

-285.56%

Last updated:

Year-over-Year Free Cash Flow Growth of Remed Co is 2025 140.28 % . Year-over-Year Free Cash Flow Growth of Remed Co was 2024 -75.60 % . It decreases by -285.56% higher compared to the previous year.

The Remed Co FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
-658.22 KRW
Jan 1, 2019
122.78 KRW
Jan 1, 2020
57.59 KRW
Jan 1, 2021
-537.93 KRW
Jan 1, 2022
105.28 KRW
Jan 1, 2023
489.94 KRW
Jan 1, 2024
-75.60 KRW
Jan 1, 2025
140.28 KRW
The Remed Co FCF Growth history
YEARFCF GrowthYoY
140.28 %-285.56%
-75.60 %-115.43%
489.94 %+365.39%
105.28 %-119.57%
-537.93 %-1,034.14%
57.59 %-53.10%
122.78 %-118.65%
-658.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Remed Co Stock analysis

What does Remed Co do? REMED Co., Ltd. generates revenue through the manufacturing and sale of medical equipment, including transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, and biosignal and monitoring machines. Pain therapy machines encompass electromagnetic stimulation machines, extracorporeal shockwave therapy machines, and high intensity laser therapy machines. Biosignal and monitoring machines include patient monitors, fetal monitors, and electrocardiogram (ECG/EKG) machines. The company distributes these products domestically and internationally, targeting healthcare providers and medical facilities that require specialized therapeutic and monitoring solutions. The firm's product portfolio focuses on advanced medical devices for neurological and pain management, as well as patient monitoring. Transcranial magnetic stimulation (TMS) therapy machines are used for neurological treatments, while pain therapy machines address chronic pain conditions. Biosignal and monitoring machines support critical patient care, with electrocardiogram (ECG/EKG) machines being a key component. These products are sold to hospitals, clinics, and medical centers across domestic and overseas markets. REMED Co., Ltd. serves healthcare institutions that require specialized equipment for diagnosis, treatment, and monitoring. The domestic market includes hospitals and clinics in Daejeon, while overseas markets extend to international healthcare providers. The company’s revenue streams are derived from direct sales of its medical equipment, with no mention of additional services or licensing agreements in the business description. Remed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Remed Co stock

Year-over-Year Free Cash Flow Growth of Remed Co is 140.28 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Remed Co since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Remed Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Remed Co

All Key Metrics — Remed Co